Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes

G. Rayman (Lead / Corresponding author), A. N. Lumb, B. Kennon, C. Cottrell, D. Nagi, E. Page, D. Voigt, H. C. Courtney, H. Atkins, J. Platts, K. Higgins, K. Dhatariya, M. Patel, P. Narendran, P. Kar, P. Newland-Jones, R. Stewart, O. Burr, S. Thomas

Research output: Contribution to journalLetterpeer-review

9 Citations (Scopus)

Abstract

The RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial found that dexamethasone 6 mg once per day for 10 days reduced deaths by one-third in ventilated patients and by one-fifth in other patients, receiving oxygen therapy. This equates to the prevention of one death in around eight ventilated patients, or one in around 25 patients requiring oxygen.

Original languageEnglish
Article numbere14378
Number of pages5
JournalDiabetic Medicine
Volume38
Issue number1
Early online date2 Aug 2020
DOIs
Publication statusPublished - Jan 2021

Fingerprint

Dive into the research topics of 'Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes'. Together they form a unique fingerprint.

Cite this